Jula Inrig Sells 445 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 445 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $37.75, for a total transaction of $16,798.75. Following the completion of the sale, the insider owned 86,311 shares of the company’s stock, valued at $3,258,240.25. This trade represents a 0.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jula Inrig also recently made the following trade(s):

• On Monday, January 5th, Jula Inrig sold 2,031 shares of Travere Therapeutics stock. The stock was sold at an average price of $40.18, for a total value of $81,605.58.
• On Wednesday, December 24th, Jula Inrig sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $42.00, for a total value of $630,000.00.

Travere Therapeutics Stock Up 1.3%

Shares of TVTX traded up $0.48 on Wednesday, reaching $36.28. The stock had a trading volume of 2,680,240 shares, compared to its average volume of 2,537,312. The company has a debt-to-equity ratio of 4.23, a quick ratio of 2.71 and a current ratio of 2.75. Travere Therapeutics, Inc. has a 12-month low of $12.91 and a 12-month high of $42.13. The firm has a market capitalization of $3.25 billion, a price-to-earnings ratio of -34.23 and a beta of 0.85. The company has a 50-day simple moving average of $35.49 and a 200-day simple moving average of $25.60.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The business had revenue of $164.86 million during the quarter, compared to the consensus estimate of $106.09 million. During the same quarter in the prior year, the company earned ($0.70) earnings per share. The firm’s quarterly revenue was up 162.1% compared to the same quarter last year. Sell-side analysts predict that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TVTX. Citigroup raised their target price on shares of Travere Therapeutics from $34.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, October 31st. TD Cowen raised their price objective on Travere Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, October 31st. HC Wainwright reiterated a “buy” rating and set a $47.00 price objective on shares of Travere Therapeutics in a research note on Friday, November 28th. Wells Fargo & Company boosted their target price on Travere Therapeutics from $27.00 to $35.00 and gave the stock an “overweight” rating in a report on Thursday, September 11th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, October 8th. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $38.71.

Institutional Trading of Travere Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TVTX. Vanguard Group Inc. raised its stake in shares of Travere Therapeutics by 10.3% in the third quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company’s stock worth $158,059,000 after purchasing an additional 619,085 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Travere Therapeutics by 27.4% during the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock valued at $41,203,000 after buying an additional 599,102 shares during the last quarter. Emerald Advisers LLC increased its holdings in Travere Therapeutics by 2.6% in the 3rd quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company’s stock worth $51,308,000 after buying an additional 55,407 shares in the last quarter. Geode Capital Management LLC raised its position in Travere Therapeutics by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,003,701 shares of the company’s stock worth $29,658,000 after buying an additional 27,040 shares during the last quarter. Finally, Stephens Investment Management Group LLC purchased a new position in Travere Therapeutics in the 3rd quarter worth about $38,232,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.